APW
NBIX icon

Aventura Private Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Aventura Private Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7K Hold
111
– – 0.01% 491
2026
Q1 		$14.6K Buy
111
+72
+185% +$9.55K 0.01% 495
2025
Q4 		$5.53K Hold
39
– – ﹤0.01% 592
2025
Q3 		$5.47K Hold
39
– – ﹤0.01% 579
2025
Q2 		$4.9K Hold
39
– – ﹤0.01% 546
2025
Q1 		$4.31K Hold
39
– – ﹤0.01% 540
2024
Q4 		$5.32K Buy
+39
New +$4.82K ﹤0.01% 503

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aventura Private Wealth's NBIX Position: Q2 2026 in Review

Aventura Private Wealth held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 111 shares worth $18.7K. The position accounts for 0.01% of the portfolio, ranked #491.

Aventura Private Wealth first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Aventura Private Wealth held 111 shares of Neurocrine Biosciences worth $18.7K as of Q2 2026.
  • Aventura Private Wealth left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.01% of Aventura Private Wealth's portfolio in Q2 2026, its #491 holding.
  • Aventura Private Wealth first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Aventura Private Wealth's 13F filing for Q2 2026, filed 15 Jul 2026.